MedTrace Logo

Straberi Microneedling For Atrophic Acne

NCT04740268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-12-06

No results posted yet for this study

Summary

This pilot study will expand knowledge and application needling using the Straberi microneedling device for the improvement of Atrophic Acne Scarring

Conditions

  • Atrophic Acne Scar

Interventions

DEVICE

Straberi

The patient's entire face will be treated with the Straberi microneedling devise. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Sponsors & Collaborators

  • Lavish Beauty

    collaborator UNKNOWN

  • Universal Skincare Institute

    lead OTHER

Principal Investigators

  • Maurice E Wright, DR · Columbia University/ Harlem Hospital HHCNYC

  • Leslie L Nesbitt · Universal Skincare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-23
Primary Completion
2023-06-30
Completion
2023-10-12
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740268 on ClinicalTrials.gov